B. Riley Issues Negative Forecast for TCMD Earnings

Tactile Systems Technology, Inc. (NASDAQ:TCMD) – Stock analysts at B. Riley dropped their Q1 2025 EPS estimates for Tactile Systems Technology in a note issued to investors on Wednesday, February 19th. B. Riley analyst K. Bauser now forecasts that the company will earn ($0.09) per share for the quarter, down from their prior estimate of ($0.08). B. Riley has a “Neutral” rating and a $18.00 price objective on the stock. The consensus estimate for Tactile Systems Technology’s current full-year earnings is $0.86 per share. B. Riley also issued estimates for Tactile Systems Technology’s Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.19 EPS, FY2025 earnings at $0.75 EPS and FY2026 earnings at $0.81 EPS.

Several other brokerages also recently weighed in on TCMD. StockNews.com downgraded shares of Tactile Systems Technology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 16th. Oppenheimer lowered Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Finally, BTIG Research downgraded Tactile Systems Technology from a “buy” rating to a “neutral” rating in a report on Tuesday, November 5th.

Tactile Systems Technology Stock Performance

Shares of TCMD stock opened at $15.05 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.80 and a current ratio of 4.36. The company has a market capitalization of $354.88 million, a price-to-earnings ratio of 21.50 and a beta of 1.20. Tactile Systems Technology has a one year low of $11.12 and a one year high of $21.10. The company’s 50-day moving average is $17.32 and its 200 day moving average is $15.65.

Tactile Systems Technology (NASDAQ:TCMD) last released its earnings results on Tuesday, February 18th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.09. Tactile Systems Technology had a return on equity of 9.37% and a net margin of 5.79%. The firm had revenue of $85.59 million for the quarter, compared to analysts’ expectations of $85.39 million.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Tactile Systems Technology by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 1,483,692 shares of the company’s stock worth $25,416,000 after purchasing an additional 4,509 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Tactile Systems Technology by 8.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 901,551 shares of the company’s stock worth $15,444,000 after buying an additional 67,934 shares during the last quarter. Wasatch Advisors LP grew its holdings in shares of Tactile Systems Technology by 9.8% in the third quarter. Wasatch Advisors LP now owns 727,194 shares of the company’s stock worth $10,624,000 after acquiring an additional 64,684 shares during the period. Royce & Associates LP increased its position in Tactile Systems Technology by 2.5% during the third quarter. Royce & Associates LP now owns 612,979 shares of the company’s stock valued at $8,956,000 after acquiring an additional 14,780 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Tactile Systems Technology by 1.5% during the third quarter. Geode Capital Management LLC now owns 558,667 shares of the company’s stock valued at $8,164,000 after acquiring an additional 8,422 shares during the last quarter. 83.43% of the stock is owned by hedge funds and other institutional investors.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.